Paper Details

  1. Home
  2. Paper Details

GM-CSF as an adjunct to autologous bone marrow transplantation.

Author: BennettC, GulatiS, PhillipsJ, Van-PoznakC

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The study found that using GM-CSF after autologous bone marrow transplantation (AuBMT) for Hodgkin's disease speeds up recovery of blood cells and is cost-effective. The study highlights the benefits of using growth factors like GM-CSF in intensive cancer treatment, particularly for patients with relapsed Hodgkin's disease undergoing chemotherapy and AuBMT. Further research is needed to optimize the use of growth factors in cancer treatment, including the timing and duration of administration.
Paper Details　
Original Abstract of the Article :
Patients with cancer can now benefit from intensive drug dosage. Intensive drug dosage has become more effective because of the availability of better anti-emetics, hematopoietic growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte CSF (G-CSF), erythropoietin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/stem.5530110105

データ提供：米国国立医学図書館（NLM）

GM-CSF as an Adjunct to Autologous Bone Marrow Transplantation

The field of cancer treatment is constantly evolving, and researchers are always seeking better ways to combat this devastating disease. This study delves into the realm of hematological malignancies, specifically focusing on the role of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients undergoing autologous bone marrow transplantation (AuBMT) for Hodgkin's disease. Like a camel navigating the vast desert, researchers are navigating the complexities of cancer treatment, seeking oases of effective therapies. This study, like a well-placed oasis, provides valuable insights into the potential benefits of GM-CSF as an adjunct to AuBMT for Hodgkin's disease.

GM-CSF: A Potential Booster for Bone Marrow Recovery

The study's findings indicate that the administration of GM-CSF after AuBMT promotes faster recovery of myeloid cells and platelets, which are crucial components of the immune system. This observation suggests that GM-CSF might play a vital role in enhancing the efficacy of AuBMT in patients with relapsed Hodgkin's disease.

GM-CSF: A Cost-Effective Treatment Option

This study also examined the cost-effectiveness of GM-CSF and found that it is a cost-effective treatment option for patients with relapsed Hodgkin's disease who have undergone intensive chemotherapy and AuBMT. This finding is particularly significant in today's healthcare landscape, where cost-effectiveness is a major concern.

Health Implications and Applications

These findings suggest that GM-CSF could be a valuable tool in the arsenal of clinicians treating patients with relapsed Hodgkin's disease. However, more research is needed to optimize the dosage, duration of treatment, and timing of administration of GM-CSF.

Dr. Camel's Conclusion

This study, like a guiding star in the night sky, provides a valuable beacon of hope for patients with relapsed Hodgkin's disease. It highlights the potential of GM-CSF as a cost-effective and beneficial adjunct to AuBMT, paving the way for future research to refine its use and improve patient outcomes.

Date :
  1. Date Completed 1993-04-23
  2. Date Revised 2005-11-16
Further Info :

Pubmed ID

8457776

DOI: Digital Object Identifier

10.1002/stem.5530110105

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.